Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Maximilian Konig and Philip Robinson.
Maximilian Konig
Connection Strength
1.501
Philip Robinson
  1. Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al. Ann Rheum Dis. 2020 May 31.
    View in: PubMed
    Score: 0.885
  2. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020 12; 16(12):1185-1204.
    View in: PubMed
    Score: 0.229
  3. Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020 10; 79(10):1386-1388.
    View in: PubMed
    Score: 0.220
  4. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol. 2020 07; 16(7):659-666.
    View in: PubMed
    Score: 0.056
  5. A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. ACR Open Rheumatol. 2020 Aug; 2(8):491-495.
    View in: PubMed
    Score: 0.056
  6. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist. Ann Rheum Dis. 2020 06; 79(6):734-736.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.